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 diseases are a global epidemic responsible for 
17.7 million deaths

 worldwide annually, and are predicted to 
remain one of the leading causes of mortality in the devel-
oped world1. However, the molecular mechanisms driving patho-
logical initiation and progression of these diseases are probably 
multifaceted 

and largely unknown, complicating the direction of 
treatment. Identification of the signalling cascades and molecu-
lar processes that are perturbed over the disease course in clinical 
samples and experimental models of cardiac pathology is required 





Hypertrophic cardiomyopathy (HCM) is the most commonly 
inherited heart condition. It is typically caused by mutations in genes 
coding for sarcomere proteins2. Myocardial fibrosis is a hallmark of 
HCM and is considered a major contributing factor to development 
of tachyarrhythmias and the development of heart failure3–5. Fibrosis 
often occurs naturally following other cardiovascular diseases, such 
as ischaemic and non-ischaemic cardiomyopathies, and is charac-
terized by cardiac fibroblast overproliferation, myofibroblast activa-
tion and increased deposition of fibrous extracellular matrix (ECM) 
proteins6. Recent studies on early-stage HCM models and patients 
have provided insight into the direct interplay between sarcomere 
mutations and fibrosis that may precede the development of cardiac 
hypertrophy7. These mechanisms include activation of pro-fibrotic 
pathways and increased collagen synthesis beore visible structural 
cardiac remodelling. implicating fibrosis as a primary contributor to 






lying molecular signalling mechanisms driving fibrotic progression, 
which are attractive as potential targets of therapeutic intervention, 
remain poorly understood.
Understanding and targeting perturbed signalling cascades 
in patients is of crucial clinical importance. In addition to the 
high-throughput profiling of clinical samples in search of new diag-
nostic and therapeutic modalities, future screening, testing and 
validation of large numbers of potential therapeutics from exist-
ing chemical libraries will require a model of cardiac fibrosis that 
is both simple and representative, and a reproducible methodology 
to record and analyse molecular changes that occur as a result of 
pathological onset or chemical intervention.
Recent advances in tissue engineering and microfabrication 
technologies have contributed to the emergence of organ-on-a-chip 
(OOC) models for emulating human biology9. This technique 
enables the development of three-dimensional (3D) biomimetic 
systems with intricate structural and functional characteristics of 
human organs. The recently developed Biowire II, a heart-on-a-chip 
model for cultivating miniaturized engineered cardiac tissues, uses 
human induced pluripotent stem cell (hiPSC)-derived cardiomyo-
cytes to generate cardiac tissue capable of promoting structural 
and functional maturation10,11. Biowire II can capture pathological 
contractile phenotypes using tissue derived from patients with left 
ventricular hypertrophy or biomimetic disease conditions12. The 
Biowire model has also shown increased utility in high-content 
screening of large numbers of potential therapeutics by screening 
a library of kinase inhibitors for their effects on cardiac function13, 
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compared with the commonly used 2D-monolayer cardiomyocyte 
culture. We also recently demonstrated that fibrotic Biowires cap-
ture key functional hallmarks of fibrosis, including increased myo-
fibroblast presence, collagen deposition and stiffness in fibrotic 
Biowires compared with controls14.
Identifying global signalling-pathway perturbations at the phe-
notypic level in patient samples and disease models requires the use 
of precision mass spectrometry-based proteomic and systems biol-
ogy approaches. Implicit to the entire OOC field is a hypothesis that 
OOC devices with human cells are more similar at the protein level 
to native human tissues compared with commonly available rodent 
models and that these similarities will enable facile and correct iden-
tification of small-molecule effects on human tissues. In this study, 
we set out to test this hypothesis for the Biowire heart-on-a-chip 
model.
Additionally, phosphoproteomic approaches provide even more 
complete coverage by enabling monitoring of protein phosphoryla-
tion involved in quick and reversible control of molecular signal-
ling, as we have previously demonstrated15. Relatively few studies 
to date have examined phosphorylation dynamics in heart tissue 
explants, including a single analysis of a pressure-overload mouse 
model16, examination of β-adrenergic signalling in mouse cardiac 
tissue17, and several profiling clinical samples18–20. Although several 
prominent proteomic profiling studies have been conducted on car-
diomyocytes derived from induced pluripotent stem cells21,22, to our 
knowledge, there are no global phosphoproteomic studies exam-
ining OOC models of cardiac disease, obscuring their correspon-
dence to human disease.
We report the development and application of an unbiased quan-
titative mass spectrometry-based workflow, which is standardized 
from sample preparation to data analysis and designed for parallel 
monitoring of signalling pathways in quantity-limited OOC cardiac 
fibrosis models, clinical samples and animal tissue. Using deep global 
phosphoproteomic profiling as a unified and mechanistically infor-
mative framework, we analysed and characterized the signalling per-
turbations in the Biowire model of fibrotic cardiac tissue compared 
with cardiac specimens from patients with HCM and an established 
transverse aortic constriction (TAC) mouse model of cardiac hyper-
trophy and fibrosis. All disease-affected sample types were compared 
with matched non-pathological control tissues. This systematic anal-
ysis resulted in the identification and relative quantification of thou-
sands of proteins, phosphoproteins and phosphorylation sites across 
the complete sample cohort. Furthermore, for each set of analysed 
experiments, the generation of deep quantitative data enabled statis-
tical pathway-enrichment analysis, revealing selective disruptions in 
dozens of specific biological processes and signalling pathways, pro-
viding potentially clinically actionable information on the progres-
sion and maintenance of fibrotic mechanisms in cardiac pathology.
Among the panel of affected kinases in cardiac fibrosis remodel-
ling indicated by phosphoproteomic analysis of the different sample 
types, altered protein levels and differential expression of phosphor-
ylation sites within consensus motifs targeted by glycogen synthase 
kinase 3 (GSK3) indicated a role of this kinase as a key mediator 
of fibrosis. To confirm the physiological relevance of the analysis 
and validate the efficacy of our model system in screening new 
anti-fibrotic compounds, we evaluated four unprofiled GSK3 inhib-
itors from a well-characterized small-molecule kinase-inhibitor 
library23. The Biowire II model enabled non-invasive screening of 
potential anti-fibrotic compounds based primarily on their ability 
to inhibit collagen deposition and attenuate passive tension.
In addition to enabling precise molecular analysis of clinical, 
in vitro and animal model samples, the combined (OOC, animal 
model and clinical specimen) analytical framework for explor-
ing human disease mechanisms provides a unified high-content 
approach for identifying functionally relevant clinical targets and 
for screening bioactive compounds, drug leads and potential thera-
peutics for cardiovascular diseases and other pathologies relying on 
simple-to-implement OOC models.
Results
Comparative phosphoproteome analysis. To achieve a global 
survey of signalling cascades affected by cardiac pathology and 
the onset of fibrosis, we developed a three-tiered methodology for 
comparative quantitative proteomic and phosphoproteomic profil-
ing on three sets of relevant samples and respective controls: (1) 
cardiac Biowire constructs generated using cardiomyocytes derived 
from hiPSCs, representing a fibrotic phenotype and normal con-
trols; (2) cardiac tissue acquired from patients with HCM who are 
undergoing septal myectomy and patients with left ventricular out-
flow tract (LVOT) obstruction who underwent myectomy surgery 
(unfolded aorta is used as non-HCM control); and (3) heart tis-
sue from 12-week-old mice that have undergone TAC for 4 weeks 
(resulting in cardiac hypertrophy) and control sham-treated mice 
(Fig. 1). Due to the low protein amounts associated with small OOC 
tissues and the heterogeneity associated with tissue explants requir-
ing increased reliability of quantification, we subjected the clinical 
samples, TAC mouse heart tissue and cardiac Biowire constructs 
to a phosphoproteomic multiplexing strategy based on isobaric 
chemical-tag labelling (TMT) (see Methods). To increase cover-
age, samples were also prefractionated using HILIC to resolve the 
mixtures of negatively charged phosphopeptides24. Finally, due to 
the low relative abundance of phosphopeptides and mass spectrom-
etry signal suppression arising from the increased negative charge 
resulting from the phosphate moiety, an additional round of affinity 
enrichment of phosphopeptides was performed using immobilized 
TiO2 affinity chromatography. A schematic of the experimental 
workflow is presented in Fig. 1.
Fibrosis in analysed samples. Engineered Biowire control and 
fibrotic tissues were constructed using hiPSC-derived cardiomyo-
cytes and human cardiac fibroblasts in a hydrogel designed on 
the basis of mechanical property tests25,26. Over the course of cul-
turing, fibroblasts remodel the tissue structure differently in the 
normal and fibrotic tissues, as indicated by tissue compaction and 
polymer-wire bending (Supplementary Fig. 1). The gel compaction 
in fibrotic tissues is significantly

 faster than in the controls, and the 
deflection of polymer wires caused by the cell-tractional forces as 
measured by passive tension is consistently larger in the fibrotic 
Biowires compared with the controls (Supplementary Fig. 1). This 
is accompanied by a markedly lower active contractile force in the 
fibrotic group compared with the control group (Supplementary 
Fig. 1). Passive tension in the fibrotic tissues continues to increase 
with time in culture after the tissue dimension has stabilized, indi-
cating ongoing fibrotic remodelling (Supplementary Fig. 1).
Second-harmonic generation (SHG) is a label-free quantita-
tive imaging technique used to visualize collagen content at tissue 
level. An increase of fibrillar collagen accumulation was visual-
ized by SHG under a laser-scanning microscope in the fibrotic 
Biowire tissues compared with the control group (Fig. 2a). Similarly, 
collagen-rich areas were more abundant in cardiac sections from 
patient and four-week post-TAC mouse compared with control 
groups (Fig.  2b,c). The fibrotic tissues deposited increased ECM 
glycoproteins indicative of fibrotic plaque development, as deter-
mined by immunofluorescence staining with wheat germ aggluti-
nin (WGA) (Supplementary Fig. 2). Similarly, immunofluorescence 
imaging of patient and four-week post-TAC mouse cardiac sections 
stained for WGA and α-actinin revealed more infiltrating fibrosis in 
the cardiac myocytes in pathological hypertrophy (Supplementary 
Fig. 2) and a more disorganized sarcomeric pattern.
Overview of proteomic and phosphoproteomic coverage in 
analysed samples. We identified 6,587 proteins and phosphoryla-
Q9
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tion sites on 5,500 phosphoproteins in cardiac Biowire constructs, 
4,185 proteins and 3,594 phosphoproteins in patient samples, and 
3,630 proteins and 2,031 phosphoproteins in mouse heart tissue 
(Supplementary Data 1 and 2). From the parallel proteomic analy-
sis, a total of 9,266, 6,266 and 4,701 

proteins and/or phosphopro-
teins were identified in cardiac Biowire constructs, patient explants 
and mouse cardiac tissue, respectively (Fig. 3a). Hundreds of sta-
tistically significant changes (P < 0.05, two-tailed Student’s t-test, 
determined in Perseus) at both protein and phosphorylation-site 
levels were observed between the control versus pathological con-
Q10
ditions in the different datasets (Fig. 3b, Supplementary Fig. 3 and 
Supplementary Data  1 and 2). The higher throughput and lower 
variability in the multiplexed measurements demonstrate the util-
ity of our approach when dealing with samples limited by protein 
amount (that is, OOC and patient explants) as indicated by the high 
degree of quantitative value distribution and correlation across all 
sample types (Supplementary Fig. 4).
Global data comparison. In direct comparisons of the differ-
ent datasets, the Biowire OOC model system exhibited more 
consistent and distinct changes when comparing samples with 
respect to both global protein expression and phosphorylation 
levels (Figs.  3b and   4). In the three samples from the cohort of 
patients with HCM carrying a heterozygous truncating mutation in 
MYBPC3, we observed a consistent decrease at both the protein and 
phosphorylation-site level for MYBPC3 compared with unfolded 
aorta LVOT control and patients with HCM without the MYBPC3 
mutation in patient dataset 1 (Fig. 3c and Supplementary Table 1).


Additionally, a large overlap at both identified protein and 
phosphoprotein and functional annotation levels was observed 
between the Biowire phosphoproteome and proteome and another 
recent proteomic dataset in the context of induced pluripotent stem 
cell-derived ventricular cardiomyocytes (Supplementary Fig.  5), 
with the presented Biowire datasets providing deeper coverage and 
more reliably quantifiable phosphoprotein and proteins due to our 
TMT-labelling strategy22.
Supervised and unsupervised statistical analyses of the merged 
proteomic and phosphoproteomic datasets obtained for the Biowire 
model system were visualized using hierarchical clustering (Fig. 4a 
and Supplementary Fig.  3) and principal component analysis 
(Fig.  4b), respectively. The control specimens clearly segregated 
from samples reflecting pathological conditions, and the segregation 
was most distinct in the Biowire OOC group, which is important for 
downstream drug discovery studies. In the case of the patient sam-
ples and mouse heart tissue, while there is no clear discrimination 
based on hierarchical clustering, class separation was observed with 
principal component analysis, albeit with a smaller proportion of 
components. For the clinical data, the reference samples were gen-
erally more similar to each other, while there was higher variability 
among the HCM specimens, in line with the observed heterogeneity 
associated with the phenotypic manifestation of HCM.
Pathway-level comparison. A statistical overrepresentation test 
was applied to systematically evaluate the biological annotations 
corresponding to the totality of acquired data (that is all identified 
proteins and phosphoproteins) across all sample types or datas-
ets27. Notably, substantial overlap was observed among overrepre-
sented annotations associated with Reactome pathways28 and Gene 
Ontology (GO)29,30 for biological process, subcellular distribution 
and protein function terms (Fig.  5a and Supplementary Data  3). 
Commonly identified enrichments revealed structural, signalling, 
ion-binding, ion-channelling and metabolic proteins in dispa-
rate subcellular locations, ranging from the plasma membrane to 
individual organelles, many with established links to heart muscle 
and cardiac tissue function. Protein and phosphoprotein cover-
age in Biowire cardiac constructs revealed high combined annota-
tion overlap with the other two tissue datasets (that is, 73.7% for 
Reactome pathways, 83.8% for GO biological process, 86.6% for GO 
cellular component and 88.6 % for GO molecular function).
In order to use quantitative information in functional enrich-
ment analyses, the proteomic and phosphoproteomic protein-level 
data were merged and rank-weighted on the basis of the signifi-
cance of the change between experimental conditions in all data-
sets (Fig. 5b). Enrichment analysis31 was then used in conjunction 
with a custom annotation database containing information from 
a compendium of publicly available databases (that is, GO, Kyoto 
Q13
3. Whole mouse heart lysate
TAC (n = 5)
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Set 1 (5 control, 5 fibrotic)
Set 2 (3 control, 3 fibrotic)
Set 3 (5 w/ GSK inhibitor, 5 DMSO) 
Set 1 (6 HCM, 3 LVOT)
Set 2 (6 HCM, 4 LVOT)
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Fig. 1 | overview of phosphoproteomic workflows. Septal-myectomy 
tissue explants (from patients with hypertrophic cardiomyopathy (HCM) 
and patients with unfolded aortas), cardiac Biowires (control, fibrotic and 
fibrotic treated with GSK3 inhibitor), mouse hearts (four-week transverse 
aortic constriction (TAC) and sham-treated mice) were analysed with a 
workflow based on liquid chromatography with tandem mass spectrometry. 
Ctrl, control; Expt, experimental sample; DMSO, dimethylsulfoxide; HILIC–
HPLC, hydrophilic-interaction liquid chromatography–high performance 
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Encyclopedia of Genes and Genomes, MSigDB, National Cancer 
Institute–Nature Pathway Information Database, NetPath, Panther 
and Reactome). This analysis revealed very good consistency with 
2,030, 1,485 and 1,002 differentially enriched gene sets for the 
Biowire constructs, explants and mouse cardiac tissue surveys, 
respectively (Supplementary Fig.  6 and Supplementary Data  4), 
although the overlap between all three datasets was lower (Fig. 5c).
Taking into account the design of the Biowire disease model as 
a fibrotic system, among the 444 gene set annotations commonly 
altered in all three datasets between disease and control conditions, 
several were directly related to fibrotic mechanisms and showed a 
clear trend of increased expression of individual components in the 
fibrotic samples (Supplementary Fig. 7). Importantly, an additional 
662 gene set annotations were uniquely similar between patient and 
Biowire samples, compared with 154 between mouse and human 
patient samples, further supporting a higher level of similarity 
between patient samples and Biowire, versus mouse samples. The 
444 networks common to all models included gene sets associated 
with the matrisome, an expanded set of proteins involved in ECM 
deposition, organization and processing constructed from experi-
mental observations and bioinformatic prediction of ECM proteins 
on the basis of protein-domain composition32. Further gene sets 
uniformly identified as altered across all the sample types include 
those with general terms involving cardiac muscle cell organization 
and development, cell junctions, calcium-related pathways, calmod-
ulin binding and mitochondrial function (Supplementary Data 4).
Additional enriched signalling pathways of potential relevance 
to cardiac pathology were identified in human samples, although 
not uniformly (Supplementary Data 4). These included Fcγ recep-




























































Fig. 2 | collagen deposition in normal and fibrotic samples. a–c, Representative SHG images of fibrotic and control samples (red, tissue autofluorescence; 
white, collagen; scale bar, 100 μm) and corresponding quantification. Twenty-one images were taken from seven biological replicates per group. Statistical 
significance was calculated using a two-tailed Student’s t-test. a, Representative SHG images of normal and fibrotic Biowires and corresponding 
quantification of collagen area ratio (mean ± s.d., n = 7). ****P < 0.0001. b, Representative SHG images of cardiac sections from patients with HCM that 
were unaffected (control) and affected by fibrosis (HCM), and corresponding quantification of collagen area ratio (mean ± s.d., n = 7). ***P < 0.001. c, 
Representative SHG images of mouse cardiac sections from sham-treated and four-week post-TAC mice, and corresponding quantification of collagen 
area ratio (mean ± s.d., n = 7). **P < 0.01 (P = 0.0013).
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coronary heart disease33, the class III 

histone deacetylase, with a 
protective role in cardiac injury34, β1- and β3-integrin signalling, 
with established roles in cardiac fibrosis35, focal adhesion kinase 
(FAK) signalling, involved in early-stage cardiac hypertrophy36, and 
chemokine receptor CXCR4 signalling, with proposed roles in tar-
geting and proliferation of progenitor cells in cardiac pathologies37. 
These latter observations point to limitations of model systems in 
relation to profiling human disease.
Although occasionally identified across the different datasets, 
disparate signalling pathways associated with the initiation and 
progression of cardiac fibrosis were identified as significantly dis-
turbed between the control conditions and mouse and Biowire 
experimental conditions (Supplementary Data  4), suggesting 
Q15 plausible therapeutic targets. The cumulative data provided quan-
titative information of individual protein and phosphorylation-site 
components of pathways associated with the interplay of signalling 
networks previously linked to fibrosis, including the interrelated 
TGFβ, WNT, β-catenin, SMAD2/3, Hedgehog, integrin-linked 
kinase, FAK, MAPK and PI3K–AKT–mTOR signalling cascades38.
Kinase target identification. Common motifs present among 
the three sample groups identified kinases central to cardiac con-
tractility, metabolism and signalling cascades (Supplementary 
Data  5), including consensus sequences targeted by PKA, Ca2+/
calmodulin-dependent protein kinase II (CAMKII), ERK1/2, PKC, 
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Fig. 3 | coverage and data distribution across datasets. a, Venn diagram depicting the total number of proteins identified in the corresponding proteomic 
and phosphoproteomic datasets. b, Volcano plots indicating significantly altered proteins and phosphorylation sites identified in the combined proteomic 
and phosphoproteomic datasets from Biowires, mouse heart tissue and patient explants. Negative log-transformed P-values (two-tailed Student’s t-test) 
associated with individual proteins (circle) and phosphorylation sites (filled circle) plotted against the difference in means of log2-transformed normalized 
values for individual proteins and phosphorylation sites. c, Volcano plots indicating significantly altered proteins and phosphorylation sites identified in 
the merged proteomic and phosphoproteomic datasets from subgroups of septal-myectomy explants


 (patients with HCM with a truncating MYBPC3 
mutation, patients with HCM who are negative for the mutation, and patients with unfolded aortas (UA)). Negative log-transformed P-values (two-tailed 
t-test) associated with individual proteins (circle) and phosphorylation sites (filled circle) plotted against the difference in means. MYBPC3 is highlighted 
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GSK3-inhibitor screening. GSK3-substrate consensus motifs in 
sequences surrounding phosphorylation sites showed significant 
differential expression, implicating GSK3 as a mediator of fibrotic 
remodelling (Fig.  6, Supplementary Fig.  8 and Supplementary 
Data 5). To test the efficacy of the Biowire model system for screen-
ing multiple non-profiled compounds from a kinase-inhibitor 
set against a putative target, we evaluated four GSK3 inhibitors 
(GW806290X, GW827102X, GW827099X and GW828529X) from 
a small-molecule kinase-inhibitor library23, together with a stan-
dard commercially available inhibitor (CHIR 99021) of GSK3. The 
aim was to obtain an initial proof-of-concept selection of drugs 
that effectively alter fibrotic remodelling and to provide important 
exploratory data for later trials that use different dosages and time 
points.
Considering the time-dependent nature of collagen deposition 
and fibrotic modelling, two time courses for GSK3-inhibitor treat-
ment were investigated, specifically (1) late application of the inhib-
itors to already-established fibrotic tissue and (2) early application 
of the inhibitors at the time of tissue formation to mimic a fibrosis 
prevention scenario.
In (1), to assess drug effects on established fibrosis, fibrotic tis-
sues were cultivated for six weeks under electrical conditioning 
before treatment as described previously14 (Fig. 6a). We then per-
formed a selection from the non-profiled inhibitors by evaluating 
compound efficacy in reducing collagen deposition and myofibro-
blast activation (Supplementary Fig.  9). The GW806290X-treated 
group showed the most significant

 reduction in deposited collagen 
in the model of already-established fibrosis, whereas the other three 
compounds exhibited modest or no effects on collagen inhibition, 
which may be related to either off-target effects or reflect the dif-
ficulty of reducing already-established fibrosis (Supplementary 
Fig.  9a,b). Passive tension was also used as a direct readout of 
fibrotic ECM remodelling in Biowires, as it is observed to be con-
sistently higher in the fibrotic Biowires14 (Supplementary Figs.  1 
and 8a). Compound GW806290X displayed the most potent effect 
in reducing passive tension among all GSK3 inhibitors after 7 d of 
treatment after maturation (Supplementary Fig. 8b), while having 
no negative effects on active tension (Supplementary Fig. 8c).
The anti-fibrotic efficacy of GW806290X was further validated 
and compared with a parallel treatment with the standard GSK3 
inhibitor CHIR 99021. Similar trends in diminishing collagen 
deposition were observed in both treatment groups (Fig. 6b,c). By 
contrast, there was no statistically significant difference in myofi-
broblast activation between the control and GW806290C and CHIR 
Q18
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Fig. 4 | comparison of merged proteomic and phosphoproteomic datasets between experimental and clinical conditions. a, Euclidian-distance-based 
hierarchical clustering of significantly altered (P < 0.05) proteins and phosphorylation sites in representative datasets. FB, fibroblasts. b, Principal component 
analysis of all merged proteomic and phosphoproteomic data in individual datasets.
NAtURE BioMEDicAL ENGiNEERiNG | www.nature.com/natbiomedeng
A B




































































99021 groups (Fig. 6d,e), indicating a limited ability to profoundly 
reduce already-established fibrosis and scarring over the time 
course of drug treatment that was investigated here (one week).
In (2), to investigate more effective treatment timelines and 
early intervention in fibrosis, treatment was also performed upon 
cell seeding (Fig.  7a). Significant inhibition of collagen deposi-
tion and a marked suppression of myofibroblast activation were 
observed after 7 d of treatment with both compounds (Fig. 7b–e), 
as expected. Fibroblast-guided tissue compaction reflects early 
fibrosis formation, with fibrotic Biowires showing faster and denser 
compaction12,14 (Supplementary Figs.  1 and 8a). Slowing of tissue 
compaction was observed after early treatment with GW806290X 
and CHIR 99021 on seeding (Supplementary Fig. 8d), accompanied 
by significantly lower passive tension developed at 7 d in culture 
(Supplementary Fig. 8e), albeit with a diminishing active force as a 
side effect of reduced gel compaction (Supplementary Fig. 8f).
Phosphoproteomic analysis of fibrotic Biowires treated with 
GW806290X (Supplementary Figs.  3 and 4) revealed a marked 
decrease of significantly altered GSK3-targeted phosphorylation 
sites (Supplementary Fig.  10a and Supplementary Data  5) and 
decreased collagen expression as a result of treatment compared with 
controls (DMSO-treated cells; Supplementary Fig. 10b). Consistent 
with this, unsupervised hierarchical clustering and Gene Set 
Enrichment Analysis (GSEA) revealed a reversal of pathway-level 
phenotypes mimicking the differences seen between control and 
fibrotic Biowires from datasets 1 and 2 (Fig. 5c and Supplementary 
Figs.  6 and 7). While the number of altered targets of GSK3 
(Supplementary Fig. 3 and Supplementary Data 1 and 2) between 
the GW806290X-treated and untreated fibrotic Biowires was lower 
than other comparisons (that is, fibrotic versus control Biowires, 
patient explants and TAC versus sham treatment), consistent with 
the well-established concept that multiple kinases phosphorylate 
the same sites and the complex interplay of compensatory mecha-
nisms when a single kinase is specifically blocked, GSK3-targeted 
sites on several proteins with known roles in GSK3 signalling and/




















































































































































































































































Fig. 5 | Pathway-level comparison between datasets. a, Identification-coverage comparison of significantly enriched (P < 0.05) annotations between 
datasets. Heat maps represent fold enrichment of protein or phosphoprotein IDs in the datasets over normal occurrence in the proteome. b, Venn diagram 
of overlap between GSEA significantly enriched gene sets (P < 0.05) and Euclidian-distance hierarchical clustergram heat map representing normalized 
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of treatment (Supplementary Fig.  10c). These included: RB1CC1, 
with a reported role in cardiac development42, YWHAB, a member 
of the 14-3-3 protein family involved in multiple MAPK-signalling 
pathways, NRSF/REST, a transcriptional repressor with an estab-
lished role in the cardiac fetal gene-expression regulation43, TCF12/
HEB, involved in heart development and stem cell differentiation44, 
ZMYND8/PRKCBP1, previously shown to regulate HIF-1 response 
to hypoxia in the heart45.
Together, these results indicate the role of GSK3 as an actionable 
target and establish the utility of the Biowire OOC model system in 
screening and selecting suitable drug candidates.
Discussion
The identification and quantitative monitoring of global protein 
abundance and phosphorylation changes specific to a pathological 
state requires the application of modern phosphoproteomic tech-
niques. Human myocardial tissue was recently analysed on a large 
scale by mass spectrometry-based global phosphoprofiling, which 
enabled the differentiation of the molecular patterns in patients 
with ischaemic and non-ischaemic cardiomyopathy20. Systematic 
large-scale proteomic studies in mice have also been conducted to 
determine the changes in protein phosphorylation resulting from 
β-adrenergic inhibition or stimulation17, and in a model of car-
diac hypertrophy to determine changes due to pressure overload16, 
informing on the networks affected by these pathophysiological 
perturbations. A complementary targeted quantitative MS-based 
approach based on multiple-reaction monitoring has also been 
used to selectively measure mitochondrial-phosphoprotein involve-
ment in cardiac physiology in mouse and human tissue samples46. 
However, these studies have all been limited in either quantitative 
reliability, coverage or relevance to human clinical presentations. 
Indeed, while tandem mass spectrometry has been widely deployed 
for over a decade, there have been relatively few unbiased phospho-
proteomic studies performed in the context of studying cardiovas-
cular disease mechanisms, presumably due to obstacles in acquiring 
and processing patient samples and the generation of OOC models 
associated with cardiac tissue. Hence, the present study represents 
an experimental and data-analysis approach for documenting con-
sistent changes in protein, phosphoprotein and pathway dynamics 
across patient-, mouse- and OOC-derived cardiac tissue.
TMT labelling of peptides and phosphopeptides following tryp-
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Drug-screening timeline with mature Biowire tissues. b, Representative SHG images of fibrotic tissues treated with GW806290 and CHIR 99021 
compared with DMSO control after 7 d of treatment (red, tissue autofluorescence; white, collagen; scale bar=100 μm). c, Corresponding quantification 
of collagen area ratio from b (mean ± s.d., n > 5). **P < 0.01 (P = 0.0066), ***P < 0.001. d, Representative immunostaining of fibrotic tissues treated with 
GW806290 and CHIR 99021, compared with DMSO control stained for myofibroblast marker α-smooth muscle actin (α-SMA) (green), counterstained 
with the nuclear stain DAPI (blue) (scale bar, 100  μm). e, Corresponding quantification of activated myofibroblast


 fraction in total cell population from d 
(mean ± s.d., n ≥ 5). At least 15 images were taken from at least 5 biological replicates per group for all experiments. Statistical significance was calculated 
using two-tailed Student’s t-tests.
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cessive sample preparation steps, which affects the reliability of 
quantitative data, due to the mixing and subsequent equal experi-
mental handling and mass spectrometric detection of all labelled 
samples. This is especially true for phosphoproteomic workflows 
targeted to MS analyses of cardiac muscle tissue, where to ensure 
deeper coverage and protein or phosphoprotein detection, multiple 
chromatographic-fractionation and affinity-enrichment experi-
mental steps are required, each with its own set of associated techni-
cal errors. A major limiting factor of this approach, in this and other 
similar TMT- or isobaric-labelling studies, is the limited number of 
samples that can be analysed. However, the alternative to achieving 
comparable coverage, requiring the same general experimental pro-
cedure and larger sample amounts in label-free experimental work-
flows would require (compared with a TMT-10plex experiment) 
about ten times as much: protein sample from each patient or model 
system, time/labour required for chromatographic-fractionation 
steps, phosphopeptide-enrichment steps and mass spectrometry 
time; and all at the expense of quantitative reliability of the data due 
to the technical error introduced by separate processing of individ-
ual samples. The alternative approaches to the one presented here 
aiming to increasing sample sizes in phosphoproteomic analyses 
of myocardial tissue by removing or minimizing experimental and 
sample processing and/or isobaric-labelling steps would result in 
a severe decrease of the reliably quantifiable (phospho)proteome. 
Therefore, the balance of quantity (sample numbers analysed) and 
quality (phosphoproteomic coverage depth and reliability) must be 
considered when interpreting the data, as always.
Most in vitro studies of cardiac fibrosis are dependent on the 
analysis of cells grown in a 2D cell-culture environment47. However, 
the monolayer cell culture cannot adequately reproduce the actual 
disease process in a real human heart due to oversimplification of 
the extracellular microenvironment26. Mechanisms governing ECM 
remodelling, myofibroblast activation and contractile functions can 
only be fully recapitulated with representative 3D scale models48. 
With the aim of discovering mechanisms of cardiac fibrosis and 









































































Fig. 7 | Drug screening with early treatment upon tissue seeding. a, Drug-screening timeline of early treatment. b, Representative SHG images of fibrotic 
tissues treated with the selected GSK3 inhibitor GW806290X in parallel with CHIR 99021 for 7 d upon seeding compared with DMSO control (red, tissue 
autofluorescence; white, collagen; scale bar, 100 μm). c, Corresponding quantification of collagen area ratio from b (mean ± s.d., n > 5). ***P < 0.001. 
****P < 0.0001. d, Representative immunostaining of tissues treated with GW806290X and CHIR 99021 for 7 d upon seeding, compared with DMSO 
control stained for the myofibroblast marker α-SMA (green), counterstained with the nuclear stain DAPI (blue). (scale bar, 100 μm). e, Corresponding 
quantification of activated myofibroblast fraction in total cell population from d (mean ± s.d., n ≥ 5). ***P < 0.001, **P < 0.01 (P = 0.0068). At least 15 
images were taken from at least 5 biological replicates per group for all experiments. Statistical significance was calculated using two-tailed Student’s 
t-tests.
NAtURE BioMEDicAL ENGiNEERiNG | www.nature.com/natbiomedeng
A B



































































Articles Nature Biomedical eNgiNeeriNg
designed as a model system for constructing a fibrosis-on-a-chip 
model which contains more sophisticated topographic and biome-
chanical cues than cells on flat dishes.
The majority of proteomic studies of fibrosis to date have uti-
lized patient plasma or conventional cell culture, which are insuf-
ficient to obtain the comprehensive data of complex signalling 
leading to ECM remodelling in healthy and pathological tissues49. 
As demonstrated here, the combination of an OOC disease model 
with authentic ECM cues and refined phosphoproteomic and com-
putational techniques have facilitated an in-depth systems-level 
profiling of the molecular networks in the cardiac fibrosis process, 
recapitulating similar events observed in patient explants and the 
TAC mouse model. This combined strategy has provided informa-
tion that may lead to new insights into the early detection and pre-
diction of fibrotic remodelling events.
By generating quantitative data on thousands of proteins and 
phosphorylation sites we were able to generate an in-depth profile 
of molecular pathways and factors underlying cardiac fibrosis uti-
lizing both proteomic and phosphoproteomic analyses of patient 
explant, TAC mouse model and Biowire tissues. Using this strategy, 
we have provided a framework for future studies of cardiac fibro-
sis and a guide for future investigations on a variety of pathways 
(for example, pathways mediating electrotonic interactions between 
myofibroblasts and cardiomyocytes or regulation of fibrillar-protein 
deposition).
The cross-platform disease-modelling strategy will enable new 
insights into a wide variety of cardiac disease mechanisms, as well 
as provide a test bed for screening new therapies and potentially cut 
the cost and time of bringing new drugs to market. We were able 
to select compounds targeting a pathway identified through phos-
phoproteomic profiling. By evaluating the anti-fibrotic efficacy of 
a list of non-profiled GSK3 inhibitors from the GlaxoSmithKline 
published kinase inhibitor set23 along with a standard commer-
cially available inhibitor, we show the potential application of the 
fibrosis-on-a-chip model in preliminary compound screening. 
Anti-fibrotic effects of compounds can be studied at tissue level as 
well as molecular level with simplified functional assessment and 
sequential comprehensive phosphoproteomic analysis.
This study involves phosphoproteomic analyses of an OOC 
model system and of animal and human tissue, and provides an 
overview of dysregulated phosphorylation cascades in relation to 
myectomy samples from patients suffering from HCM and the most 
comprehensive phosphoproteomic analysis of the most commonly 
utilized mouse model of cardiac hypertrophy. More importantly, 
utilizing a combination of modern bioengineering, proteomic, and 
computational techniques, we have developed a multi-pronged 
approach for the reproducible characterization of potential thera-
peutics and their effects on central cardiac-signalling pathways that 
can be related back to human clinical samples and tissues from ani-
mal models of cardiovascular diseases. Thus, with appropriate mod-
ifications, this methodology is not limited to the study of cardiac 
fibrosis alone, but can potentially be applied to investigate a variety 
of other cardiac and other pathologies.
Methods
Biowire generation and preparation. 


Biowire tissues were generated starting 
from cardiomyocytes derived from the hiPSC line BJ1D and human ventricular 
fibroblasts13. Cardiomyocytes were mixed with cardiac fibroblasts in 3:1 (control) 
and 1:3 (fibrotic) cell-number ratios in a mixed hydrogel as previously described12. 
After seeding, the engineered cardiac tissues were cultured for 7 d to allow for 
remodelling and compaction around the poly(octamethylene maleate (anhydride) 
citrate) (POMaC) wires. By day 7, the Biowires synchronously contracted and 
deflected the POMaC wire with each contraction. Biowires were washed five times 
in PBS and resuspended in 8 M urea containing a phosphatase (PhosStop, Roche) 
and Dounce homogenized to ensure the separation of fibrotic clots and contractile 
apparatus proteins from other intracellular proteins. The lysates were cleared of 
the cellular debris and protein aggregates by centrifugation at 13,000g for 10 min at 
4 °C (repeated three times). Centrifugation was repeated until no visible pellet was 
Q19
present. The supernatant was frozen at −80 °C for further processing. Passive force 
and active tension were determined from polymer-wire deflection as described12,13. 
For phosphoproteomic mass spectrometry analysis, 5 individual Biowires were 
combined as a single replicate to obtain 100 μg protein.
SHG imaging and collagen quantification. Biowires and tissues were fixed with 
4% paraformaldehyde and imaged by a SHG laser-scanning microscope (Zeiss 
LSM710 wo-Photon/Confocal microscope). A two-photon laser tuned to 860 nm 
was attached to the microscope and resulted in a SHG signal that was detectable at 
475 nm. Quantification of collagen fibres was performed with ImageJ. A minimal 
threshold was set to segment the second-harmonic signal. The threshold was 
maintained for all images across all conditions. The ratio of thresholded collagen 
area to total tissue area was calculated and three images per sample were averaged 
together. Statistical analysis was performed using Prism 7.0.
Immunostaining. Biowire constructs were fixed with 4% paraformaldehyde, 
permeabilized with 0.25% Triton X-100 and blocked with 5% BSA. Immunostaining 
was performed using mouse anti-sarcomeric α-actinin (EA-53) (Abcam, catalogue 
(cat.) no. ab9465; 1:200), mouse anti-type I collagen (GeneTex, cat. no GTX26308; 
1:200), rabbit anti-smooth muscle actin (Abcam, cat. no. ab5694; 1:200) primary 
antibodies, together with donkey anti-mouse IgG heavy and light chain (Alexa 
Fluor 488) (Abcam, cat. no. ab150105; 1:400) and donkey anti-rabbit IgG heavy 
and light chain (Alexa Fluor 488) (Abcam, cat. no. ab150073; 1:400) secondary 
antibodies. Nuclei were counterstained with DAPI (Biotium; 1: 100). For confocal 
microscopy, the stained cardiac Biowires were visualized under an inverted confocal 
microscope (Olympus IX81) or an upright confocal microscope (Zeiss LSM510).
Sham and four-week TAC mouse hearts were fresh frozen and sectioned using 
cryostat. After fixing with 10% formalin and permeabilization with 0.1% Triton 
X-100, primary antibody (α-actinin; ThermoScientific, 1:400) was incubated for 
2 h at room temperature. Secondary antibody (Alexa Fluor 647, mouse; 1:100) was 
subsequently incubated for 1 h at room temperature. WGA was added dropwise 
and incubated for 1 h at room temperature. Slides were mounted using Cytoseal 60 
and imaged using Zeiss spinning-disk confocal microscope.
Mouse heart tissue sample preparation. All animal experiments were conducted 
in accordance with the Animal Care Guidelines approved by the University 
of Toronto Animal Use and Care Committee. In brief, 6- to 8-week-old male 
CD1 (Charles River Laboratories) mice were randomly assigned to either sham 
or TAC experimental groups. All mice were then anaesthetized using 1.5% 
isoflurane and TAC was applied by placing a 7-0 silk suture around the transverse 
aorta. Successful TAC was confirmed by Doppler blood flow velocity via 
echocardiogram. Further echocardiographic assessment of cardiac function was 
performed (Supplementary Data 6) using B-mode and M-mode echocardiographic 
measurements (Vevo2100 imaging system, Visual Sonics). Four weeks following 
surgery, five TAC mice and five sham mice were killed using CO2 and hearts 
were collected after surgery for phosphoproteomic analysis. Hearts were isolated 
and washed with ice-cold PBS. They were subsequently snap-frozen in liquid 
nitrogen and stored at −80 °C. Each frozen heart was mechanically homogenized 
with a homogenizer (PRO 200; PRO Scientific) in 1 ml of 8 M urea solution with 
protease (Sigma) and phosphatase inhibitors (PhosSTOP; Roche). They were 
then centrifuged at 13,000g for 10 min and the supernatant was removed. The 
centrifugation step was repeated until no visible pellet was present to collect 
intracellular protein content and remove cellular debris, contractile apparatus 
proteins and any fibrotic clots that would interfere with mass spectrometry analysis 
due to an increased dynamic range of protein levels and resulting ion suppression. 
The supernatant was frozen at −80 °C for further processing.
Patient tissue sample preparation. Patients that had undergone genetic testing for 
a panel of HCM genes were asked for consent for tissue collection at the time of 
septal myectomy under the institutional research ethics board approval (University 
Health Network, REB #13-6800). Tissue explants were collected immediately 
following resection, snap-frozen and stored in liquid nitrogen. Fifty milligrams 
of tissue was processed in the same manner as the mouse hearts described above. 
Anonymized clinical data were also collected. Tissue samples were grouped as ‘gene 
positive’ if specific pathogenic mutations were identified at the time of genetic 
testing, ‘gene negative’ if gene testing was negative, or LVOT controls as a result of 
unfolding of the aorta creating a specific septal geometry.
Protein digestion. Bradford total protein assay (Bio-Rad) was performed to 
determine the total protein content in each sample. One-hundred micrograms 
of protein from individual samples were used. 


A final concentration of 
2.5 mM DTT was added to reduce two proteins from each sample for 60 min 
at room temperature. Iodoacetamide was then added to each sample to a 
final concentration of 5 mM for alkylation and incubated for 30 min at room 
temperature in the dark. Lastly, samples were diluted in 50 mM ammonium 
bicarbonate (to bring the urea concentration below 1 M) before the addition of 
1:20 protein:protein ratio of sequencing-grade trypsin (Promega) for overnight 
digestion at 37 °C. Formic acid was added to 1% in the sample solutions to block 
trypsin activity. Digested peptide fragments were isolated and desalted with C18 
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TopTips (Glygen). All samples were dried to completion by SpeedVac (Thermo). 
Cardiac tissue samples were resuspended in 80% acetonitrile (ACN) with 0.1% 
triflouroacetic acid (TFA) and individual samples were subjected to HILIC–HPLC 
fractionation (that is, six separate HILIC–HPLC runs). Biowire and patient explant 
samples were subjected to TMT labelling.
TMT labelling. One-hundred micrograms of total protein (per TMT label), as 
determined by the Bradford total protein assay, from Biowire (five Biowires per 
TMT channel), patient explant and mouse tissue samples were labelled with 
TMT10-plex reagents as described by the manufacturer (Thermo). In brief, 
dried peptides in each sample were resuspended in 100 μl of triethylammonium 
bicarbonate (Sigma), individual TMT labels were resuspended in 41 μl of ACN 
and added to the corresponding samples, the labelling reaction was allowed to 
proceed for 1 h at room temperature, the reaction was stopped by quenching with 
8 μl of 5% hydroxylamine (Sigma) and the individual samples were combined for 
each sample-type group (that is, Biowire constructs, patient explants and mouse 
cardiac tissue). The combined samples were dried to completion by SpeedVac and 
resuspended in 80% ACN with 0.1% TFA for HILIC fractionation.
Fractionation and phosphopeptide enrichment. HILIC fractionation for all 
sample types (1 mg of total protein per TMT dataset) was conducted using a 
2.0 × 150 mm 5 μm particle TSKgel Amide-80 column (Tosoh Biocience) with an 
Agilent 1200 HPLC system. Two mobile phases were used: buffer A, composed 
of 98% ACN, 0.1% TFA and buffer B containing 2% ACN and 0.1% TFA. One 
milligram of digested peptides was loaded onto the column at a flow rate of 
250 μl min−1. The liquid chromatography was set up in the following manner: 
3 min loading in 20% buffer B, a gradient of 20-40% buffer B for 27 min, a 3 min 
gradient of 40–100% buffer B, 100% buffer B for 5 min, 100–20% buffer B gradient 
for 2 min, and finally 10 min of 20% buffer B. Eluted samples were fractionated 
into 1.5 ml tubes at 2 min intervals and dried to completion. Ten percent of each 
fraction was used for global proteomic analysis. Phosphopeptide enrichment 
from resulting HILIC fractions was performed using TiO2-coated Mag Sepharose 
beads (GE Life Sciences) according to the manufacturer’s instructions. In brief, 
each HILIC fraction was dried to completion by SpeedVac (Thermo) and was 
resuspended in 200 μl of binding buffer (1 M glycolic acid, 80% ACN and 5% TFA), 
incubated with prepared magnetic beads for 1 h, washed one time with 500 μl 
binding buffer and three times with washing buffer (80% ACN and 1% TFA), 
and eluted three times in 100 μl of a 5% ammonium hydroxide solution. Eluted 
phosphopeptides were subsequently dried to completion and resuspended in 20 μl 
of 1% formic acid before liquid chromatography–mass spectrometry analysis.
TMT liquid chromatography–mass spectrometry. Resuspended phosphopeptide 
and peptide mixtures from each HILIC fraction were analysed in technical 
duplicates. The liquid chromatography component consisted of a reverse-phase 
Thermo Acclaim PepMap pre-column (2 cm length, 75 μm diameter, 3 μm C18 
beads) and a Thermo PepMap RSLC C18 analytical column (50 cm length, 75 μm 
diameter, 2 μm C18 beads) connected to an Easy-nLC 1200 system (Thermo). 
The gradient (3 h), using a flow rate of 220 nl min−1, was composed of buffer 
A (5% ACN, 0.1% formic acid) and buffer B (85% ACN, 0.1% formic acid). 
Equilibration was performed with 100% buffer A on both the pre- (20 μl) and 
analytical columns (3 μl) before each injection, followed by the nanoflow gradient 
as follows: 5–35% buffer B for 156 min, 35–100% buffer B for 9 min and 100% 
buffer B for 15 min. The EasySpray ion source (Thermo) was used to directly ionize 
peptides and phosphopeptides injected into a Q Exactive HF mass spectrometer 
(Thermo). For each selected full MS1 scan mass spectrum in profile mode 15 MS2 
data-dependent scans were acquired with HCD fragmentation at 32% normalized 
collision energy. Full scan settings used were: 120,000 resolution, maximum 
injection time of 50 ms, ion packet setting of 3 × 106 for automatic gain control, 
and a 350 to 1,450 m/z range. MS2 scan settings were: 60,000 resolution, ion packet 
setting of 1 × 105 for automatic gain control, maximum injection time of 100 ms, 
fixed first mass at 100 m/z and 1.2 m/z isolation window. Unassigned, 1+ and 
parent ions with charge states higher than 6 were excluded from MS2 analysis, and 
the dynamic exclusion range was set to 20 s. Identical liquid chromatography and 
mass spectrometry settings and methods were used for proteomic (unenriched) 
and phosphoproteomic (phosphopeptide-enriched) samples or fractions.
RAW files from all MS analyses were searched using MaxQuant v.1.6.2.0 (www.
coxdocs.org/doku.php?id=maxquant:start) against the mouse UniProt FASTA 
database (www.uniprot.org/taxonomy/10090) and human protein sequence 
database (http://www.uniprot.org/taxonomy/9606) with the use of ‘Reporter ion 
MS2’ 10plex TMT settings (0.003 reporter-ion tolerance) allowing for two missed 
trypsin-cleavage sites and variable modifications for protein phosphorylation at S, 
T and Y residues, N-terminal acetylation, asparagine and glutamine deamidation, 
and methionine oxidation. Carbamidomethylation was set as a fixed modification 
on cysteine residues. A false-discovery cutoff of 1% was used to filter for 
identified candidate peptides and phosphopeptides based on the searching of a 
reverse-sequence decoy database.
Data organization and analysis. MaxQuant search data were analysed by Perseus 
(v.1.6.0.7) and Bioconductor packages in R. Reporter ion (for TMT-labelled data) 
intensities from protein groups (for proteomic analyses) and phosphorylation 
(Ser, Thr and Tyr) sites (from phosphoproteomic analyses) MaxQuant output files 
were log2-transformed and quartile-normalized by ‘width adjustment’ in Perseus50. 
Protein and phosphorylation-site identifications were filtered by removing entries 
corresponding to reverse database identifications, potential contaminants and 
those identified by site alone. Reported values for identical phosphorylation 
sites that were identified on singly or multiply phosphorylated phosphopeptides 
were entered as separate entries. Following independent normalization, 
phosphoproteomic and proteomic datasets for each sample type were merged at the 
gene and protein level to create merged datasets (with possible multiple entries due 
to multiple identified phosphorylation sites on the identified phosphoproteins), 
which were used in subsequent hierarchical clustering (P < 0.05, all reported 
heat maps) and principal component analyses (all data). Merged datasets were 
further trimmed by removing phosphorylation sites with less than 0.7 localization 
probability and duplicate entries at the gene level were removed (that is, most 
significantly altered protein and phosphorylation sites remained). Thus processed 
merged datasets were subjected to independent biological pathway enrichment by 
GSEA31 using a custom database (http://download.baderlab.org/EM_gene_sets/)51 
carrying annotated GO biological process terms and curated pathways. Enriched 
gene sets were required to have between 10 and 500 associated components, 
P < 0.05 and false-discovery rate < 0.1. To accommodate direct comparisons, 
identified mouse proteins were mapped to human orthologues on the basis of gene 
name from the ENSEMBL database. The data are available via ProteomeXchange 
with identifier PXD016492. All hierarchical clustering was performed in Perseus 
(v.1.6.0.7) using average Euclidian distance with no constraints on row clustering 
(and column clustering where cluster trees are visualized) with data pre-processed 
with k-means, 10 iterations and a maximal number of 300 clusters.
Kinase target motif analysis. Significantly altered phosphorylation sites 
(two-tailed Student’s t-test, P < 0.05) from different experiments were annotated 
using the linear motifs function from the sequence window centred around the 
modified phosphorylation sites identifying their corresponding kinase in Perseus50.
Drug testing. Kinase inhibitors were kindly provided by GlaxoSmithKline23. Four 
different published GSK3-inhibitor compounds (GW806290X, GW827102X, 
GW828529X and GW827099X) were blindly selected from 63 compounds in the 
kit. Ten millimolar stock solution was made in sterile DMSO. The compounds were 
further diluted in maintenance medium to achieve a final inhibitor concentration 
of 1 μM, based on a previous report52. Standard GSK3 inhibitor CHIR 99021 
was purchased from Cayaman Chemical (cat. no. 131222). Ten millimolar stock 
solution was made in sterile DMSO. The compounds were further diluted in 
maintenance medium to achieve a final inhibitor concentration of 5 μM.
Reporting Summary. Further information on research design is available in 
the Nature Research Reporting Summary linked to this article.
Data availability
The main data supporting the results in this study are available within the 
paper and its Supplementary Information. All data generated during the study, 
including source data and the data used to make the figures, are available via 
ProteomeXchange with identifier PXD016492.
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